Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone Mineralocorticoid Receptor Antagonism Study
NCT06649409Phase 1Completed
- Sponsor
- Santhera Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vamorolone in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Santhera Pharmaceuticals. Primary endpoint: Ratio of Sodium to Potassium (Na/K) in Urine at Day 3. Started Jun 2024; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06649409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649409.